FLT3 and acute myeloid leukemia: Furthermore, Short Nj et al. assessed the triplet regimen comprising azacitidine, venetoclax, and gilteritinib in older ND FLT3-mutated AML patients and those of all ages with R/R FLT3-mutated AML, reporting an overall response rate of 67% (CR + CRi + MLFS) and a median overall survival (OS) of 10.5 months [30].